HCQ clinical trials will resume: WHO 

#Covid19 #WHO 

The World Health Organisation said on Wednesday that clinical trials of the drug hydroxychloroquine will resume, after having been suspended pending a safety review in the search for coronavirus treatments. 

  • Hydroxychloroquine — which has anti-inflammatory and antiviral properties — inhibited the coronavirus in laboratory experiments, but has not been proven effective in humans, particularly in placebo-controlled, randomised clinical trials considered the gold standard for data.  
  • The debate has become highly politicised, and many scientists have voiced concern. 
  • Nearly 150 doctors signed an open letter to The Lancet last week calling the article’s conclusions into question and asking to make public the peer review comments that preceded publication. 
  • The study, using data provided by healthcare data analytics firm Surgisphere, was not a traditional clinical trial that would have compared hydroxychloroquine to a placebo or other medicine. 
  • The Lancet’s editors said in a note that serious scientific questions about the study were brought to their attention and an independent audit of the data has already been commissioned. 
Print Friendly and PDF
blog comments powered by Disqus